Trials / Recruiting
RecruitingNCT05142423
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
An Open Label, Multi-center, Phase Ib/II Clinical Study of AK109 Combined With AK104 to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity in Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 198 (estimated)
- Sponsor
- Akeso · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open label, phase Ib/II clinical study of AK109 and AK104 to evaluate the safety, tolerability, effectiveness, pharmacokinetic characteristics in advanced solid tumors .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AK109+AK104 | It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study. |
Timeline
- Start date
- 2021-11-03
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2021-12-02
- Last updated
- 2025-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05142423. Inclusion in this directory is not an endorsement.